RESEARCH PROGRAM TECHNOLOGY Clause Samples
RESEARCH PROGRAM TECHNOLOGY. Subject to Section 7.1.2 below, (i) title to all inventions and intellectual property made solely by GenVec employees or its agents (including researchers at DFCI) in connection with the Research Program without inventive contribution by Fuso employees or its agents shall be owned by GenVec; (ii) title to all inventions and intellectual property made solely by Fuso employees or its agents (including researchers at Jikei University) in connection with the Research Program without inventive contribution by GenVec employees or its agents shall be owned by Fuso; and (iii) title to all inventions and intellectual property made jointly by employees or the agents of Fuso and GenVec in connection with the Research Program, shall be jointly owned by GenVec and Fuso.
RESEARCH PROGRAM TECHNOLOGY. Subject to Section 7.1.2 below, (i) title to all inventions and intellectual property made solely by GenVec employees or its agents in connection with the Research Program without inventive contribution by Fuso employees or its agents shall be owned by GenVec; (ii) title to all inventions and intellectual property made solely by Fuso employees or its agents in connection with the Research Program without inventive contribution by GenVec employees or its agents shall be owned by Fuso; and (iii) title to all inventions and intellectual property made jointly by employees or the agents of Fuso and GenVec in connection with the Research Program, shall be jointly owned by GenVec and Fuso.
RESEARCH PROGRAM TECHNOLOGY. No Research Program Technology Controlled by Pfizer or RNA Improvements or Pfizer Improvements shall be licensed or sub-licensable to the Acquirer, and no Confidential Information of Pfizer or its Representatives shall be disclosed to the Acquirer, in each case without the prior written consent of Pfizer.
RESEARCH PROGRAM TECHNOLOGY. Subject to Section 7.1.2 below, --------------------------- (i) title to all inventions and intellectual property made solely by GenVec employees or its agents (including researchers at [*]) in connection with the Research Program without inventive contribution by Fuso employees or its agents shall be owned by GenVec; (ii) title to all inventions and intellectual [*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. property made solely by Fuso employees or its agents (including researchers at [*] in connection with the Research Program without inventive contribution by GenVec employees or its agents shall be owned by Fuso; and (iii) title to all inventions and intellectual property made jointly by employees or the agents of Fuso and GenVec in connection with the Research Program, shall be jointly owned by GenVec and Fuso.
RESEARCH PROGRAM TECHNOLOGY. The Parties shall jointly own and retain the right, title and interest in and to any Inventions, Patents and Know-How pertaining to (i) a Research Product and/or a Co-Development Product invented during the conduct of a Research Program by LCB (including its Affiliates and/or Subcontractors) and/or by NextCure (including its Affiliates and/or Subcontractors), (ii) the manufacture of a Co-Development Product invented during the conduct of a Research Program or Co-Development Plan by LCB and/or by NextCure (including by their respective Affiliates and/or Subcontractors), and (iii) a Research Program Target to the extent jointly invented during the conduct of a Research Program by both LCB and NextCure (including by their respective Affiliates and/or Subcontractors) (collectively, the “Research Program Technology”). The preceding shall include the right to file applications for Research Program Patents pertaining to the Research Program Technology, and further including but not limited to any Research Program Patents that claim substance of matter of a Co-Development Product. Research Program Patents will be co-owned and filed in the names of both NextCure and LCB as joint applicants. For the avoidance of doubt, the Research Program Technology shall not include any LCB Platform Improvement Technology or NextCure Platform Improvement Technology.